<DOC>
	<DOCNO>NCT00115089</DOCNO>
	<brief_summary>This study effectiveness safety new nasal spray relief symptom seasonal allergy . The agent compare : R926112 ( novel anti-allergy medicine ) , Beconase ( beclomethasone dipropionate , establish FDA approve steroid treatment ) , inactive placebo . The study hypothesis R926112 superior placebo end week test evaluation . The study power determine R926112 compare Beconase .</brief_summary>
	<brief_title>7 Day Study Mast Cell Inhibitor , R926112 , Patients With Symptomatic Seasonal Allergic Rhinitis</brief_title>
	<detailed_description>Seven hundred fifty patient history seasonal allergy screen late summer early fall 25 site across U.S . Approximately 375 patient , base severity symptom randomize among treatment ( 150 R926112 , 150 placebo , 75 Beconase ) . During , 2-3 week prior study , patient abstain anti-allergy medication . Patients fill diary card two time per day record symptom . The entire study take 2-4 week .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Subjects must sign write informed consent form assent ( applicable ) study participation . Males female , 12 year age old Subjects must history consistent seasonal allergic rhinitis ( SAR ) fall pollen season least previous 2 year . Subjects must skin test positive relevant fall aeroallergen within past 12 month least moderate reaction define least 5 mm wheal . Nasal exam exclude significant swelling , bleeding , crust , polyps Subjects receive immunotherapy must stable maintenance regimen least 30 day screen . Adjustments regimen follow brief period miss injection normal reduction dose due vaccine refill preclude participation . Female subject childbearing potential must negative urine test pregnancy Visits 1 2 . Female subject childbearing potential sexually active expect use medically recognize birth control method throughout study : systemic contraceptive ( oral , implant , injection , patch ) , diaphragm intravaginal spermicide , cervical cap , vaginal ring , intrauterine device , condom spermicide . Females sexually active admit discretion Investigator . Acceptable birth control document subject â€™ case report form . Subjects must willing adhere dose schedule , study visit , study requirement . Clinically significant medical condition ( hepatic , neurological , hematological , renal , cardiac , gastrointestinal , endocrine , major systemic disease ) , judgment Investigator , might interfere study , require treatment make implementation protocol interpretation study result difficult . Clinically relevant abnormality laboratory result electrocardiogram ( ECG ) determine investigator Asthma require treatment inhaled , short act beta agonist alone . Female subject pregnant , try become pregnant , nursing . Nasal structural abnormality , include large nasal polyp mark septal deviation significantly interfere nasal airflow nasal surgery within past year . Upper respiratory infection within 3 week date Randomization/Visit 2 . Treatment investigational drug last 30 day date Randomization/Visit 2 . History drug alcohol abuse accord Investigator could interfere study . Mental condition render subject unable understand nature , scope , possible consequence study . Subjects unlikely comply study procedure , unable return study visit , unlikely complete study , expect plan travel outside area prevalent aeroallergen study period . History hypersensitivity steroid excipients . Use tricyclic antidepressant within past 30 day prior date Randomization/Visit 2 . Ocular herpes simplex cataract present time Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Nasal Spray</keyword>
	<keyword>Seasonal Allergic Rhinitis</keyword>
</DOC>